Aethlon Medical, Inc. — Form 10-Q Summary
Business context and reporting period. Aethlon is a clinical-stage medical therapeutics company developing its Hemopurifier for cancer and life-threatening viral infections. This filing covers the three months ended June 30, 2023, compared with the three months ended June 30, 2022; balance-sheet figures are as of June 30, 2023, compared with March 31, 2023. The company reported no revenue in the presented statements of operations.
Key financial metrics
| Metric | Three months ended June 30, 2023 | Prior comparable period / balance date |
|---|---|---|
| Operating expenses | $3.408 million | $2.906 million; up 17.3% |
| Operating loss | $3.408 million | $2.906 million |
| Interest income | $126,000 | None reported |
| Net loss | $3.282 million | $2.906 million; loss increased about 13% |
| Basic and diluted loss per share | $0.14 | $0.19 |
| Net cash used in operating activities | $2.482 million | $2.729 million |
| Cash and cash equivalents | $12.898 million | $14.533 million at March 31, 2023 |
| Working capital | $11.486 million | $13.585 million at March 31, 2023 |
| Total liabilities | $2.692 million | $2.445 million at March 31, 2023 |
Cash used in investing activities was $230,000, primarily for laboratory equipment, and financing provided $1.078 million net, mainly from the at-the-market (ATM) stock program. Total lease liabilities were approximately $1.144 million; the filing does not report other borrowings. Profit margins are not meaningful because the company reported no revenue and recorded operating losses.
Material changes and operating developments
- Operating expenses rose $502,000 year over year. General and administrative expense increased $276,000, professional fees $133,000, and payroll and related expense $94,000.
- Research and development expense, included across operating expense lines, was $679,000, down from $858,000 in the prior-year quarter.
- Under its ATM agreement, Aethlon sold 1,778,901 shares at an average $0.61 per share, raising $1.086 million net of commissions and other offering costs. Shares outstanding increased to 24,835,321 as of June 30, from 22,992,466 at March 31.
- Management said cash on hand at June 30 was expected to fund operations for at least 12 months from the financial-statement issuance date. It also expects continuing losses and negative cash flows and says additional equity and/or debt financing will be needed for the foreseeable future.
Outlook, risks and contingencies
- The company was preparing, with CRO NAMSA, for oncology clinical trials in Australia, with initial trials anticipated there. It also reported ethics-board approval for a second Indian site for its severe COVID-19 study and research into use of the device in organ preservation with 34 Lives.
- Hemopurifier supply remains disrupted: existing units expired in September 2022, and the transition to a new GNA supplier is delayed pending FDA approval of an IDE supplement. This may constrain manufacturing and trial activity.
- A U.S. COVID-19 feasibility study was terminated in 2022 because of a lack of eligible ICU patients at trial sites. The filing reports one patient completed participation in the Indian COVID-19 study.
- Clinical, regulatory and commercialization outcomes remain uncertain. The company cited risks including supplier qualification and manufacturing compliance, clinical-trial delays or failures, additional financing needs and potential dilution, intellectual-property protection, and Nasdaq listing compliance. It also noted uncertainty about effects of inflation, bank failures and the war in Ukraine.
- Management reported no pending or threatened legal proceedings and no material changes to the risk factors in its latest Form 10-K. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
- Subsequent to quarter-end, a director appointed in July received 195,414 RSUs, vesting quarterly over one year, and annual cash retainers.
Important facts for investors to verify
- Whether and when the FDA approves the IDE supplement for the new GNA supplier, and whether reliable Hemopurifier production resumes.
- Clinical-trial start dates, enrollment and progress in Australia and India, and the status and scope of the organ-transplant research.
- Actual cash burn relative to management’s stated 12-month runway, and the amount, timing and terms of future financing.
- Further ATM sales, share-count changes and other potential dilution from equity awards, options and warrants.
- Nasdaq listing compliance and any changes in regulatory, supplier, clinical or capital-market risks.